Promoted Content
Promoted Content

Find Psychiatry/Psychology Drugs in Phase III Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): S-Ketamine

            Therapeutic Area: Psychiatry/Psychology Product Name: Spravato

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 11, 2020

            Details:

            The European marketing authorisation application was based on the Phase 3 double-blind, randomised, placebo controlled, multicentre ASPIRE I & II clinical studies SPRAVATO®▼ (Esketamine Nasal Spray) in combination with comprehensive standard of care.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Roluperidone

            Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2020

            Details:

            The objective of this meeting was to obtain FDA input regarding the roluperidone data package and its readiness to support a New Drug Application (NDA) submission.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SAGE-217

            Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $3,125.0 million Upfront Cash: $1,525.0 million

            Deal Type: Collaboration November 27, 2020

            Details:

            The deal would give Biogen rights to a treatment for multiple types of depression, called SAGE-217 or zuranolone, as well as a treatment for essential tremor and other neurological disorders, called SAGE-324.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Samidorphan,Olanzapine

            Therapeutic Area: Psychiatry/Psychology Product Name: ALKS 3831

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020

            Details:

            The AdCom will likely question whether or not ALKS-3831, a formulation of samidorphan and generically available olanzapine, provided a clinically meaningful reduction in the common weight gain side effect versus olanzapine.